Vertex Pharmaceuticals (VRTX) Other Non-Current Assets (2009 - 2026)

Vertex Pharmaceuticals' Other Non-Current Assets history runs 18 years deep, the most recent figure standing at $1.3 billion for Q1 2026.

• In Q1 2026, Other Non-Current Assets rose 24.73% year-over-year to $1.3 billion; the TTM figure through Mar 2026 stood at $1.3 billion (up 24.73% YoY), while the FY2025 annual figure was $1.2 billion, up 23.75% from the prior year.
• Other Non-Current Assets for Q1 2026 stood at $1.3 billion, up from $1.2 billion in the prior quarter.
• The five-year high for Other Non-Current Assets was $1.3 billion in Q1 2026, with the low at $110.7 million in Q1 2022.
• The 5-year median for Other Non-Current Assets is $895.3 million (2023), against an average of $734.0 million.
• The sharpest annual moves came in 2023 and 2025: Other Non-Current Assets surged 286.18% in 2023, then advanced 10.89% in 2025.
• Vertex Pharmaceuticals' Other Non-Current Assets stood at $409.6 million in 2022, then jumped by 118.58% to $895.3 million in 2023, then climbed by 11.62% to $999.3 million in 2024, then increased by 23.75% to $1.2 billion in 2025, then climbed by 1.6% to $1.3 billion in 2026.
• Business Quant data shows VRTX's Other Non-Current Assets at $1.3 billion in Q1 2026, $1.2 billion in Q4 2025, and $1.1 billion in Q3 2025.